In the latest health updates, German generic drugmaker Stada considers an autumn IPO if market conditions prove favorable, as stated by CEO Peter Goldschmidt. This revival could mark a significant shift in the pharmaceutical industry's financial strategies. Gerresheimer faces investor scrutiny over its strategic direction following CFO Bernd Metzner's resignation. Wolf Lehmann, an outsider with private equity experience, will step into the role in September, potentially altering the company's financial landscape. Meanwhile, the U.S. CDC witnessed a notable leadership upheaval due to policy changes regarding vaccine advisory roles. Departing officials expressed concerns over appointments influenced by Secretary of Health Robert F. Kennedy Jr. Furthermore, global health issues are underscored by alarming food shortages for malnourished children in Africa and a surge of rare medical conditions in Gaza, alongside major drug approvals in the UK and US addressing various health concerns. (With inputs from agencies.)

Source: Devdiscourse